A Phase II Open-Label, Randomized, Parallel Group, Safety, Tolerability and Efficacy Study of I.M. Administered CHRONVAC-C in Combination With Electroporation Followed by Standard of Care in Chronic Hepatitis C Virus Genotype 1 Infected and Treatment Naïve Subjects.

Trial Profile

A Phase II Open-Label, Randomized, Parallel Group, Safety, Tolerability and Efficacy Study of I.M. Administered CHRONVAC-C in Combination With Electroporation Followed by Standard of Care in Chronic Hepatitis C Virus Genotype 1 Infected and Treatment Naïve Subjects.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Hepatitis C DNA vaccine (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Apr 2013 Interim results published in the Media Release.
    • 02 Apr 2013 Primary endpoint 'Viral-load' has not been met, according to a ChronTech Pharma media release.
    • 25 Jan 2013 Results will be reported in the first quarter of 2013 according to a ChronTech Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top